Biora Therapeutics (NASDAQ:BIOR) Price Target Raised to $23.00 at HC Wainwright

by · The Cerbat Gem

Biora Therapeutics (NASDAQ:BIOR – Get Free Report) had its price objective raised by HC Wainwright from $15.00 to $23.00 in a research report issued on Monday,Benzinga reports. The brokerage currently has a “buy” rating on the stock.

Biora Therapeutics Stock Performance

Shares of Biora Therapeutics stock traded down $0.15 on Monday, hitting $1.97. The company’s stock had a trading volume of 114,311 shares, compared to its average volume of 41,084. The company has a market capitalization of $7.25 million, a price-to-earnings ratio of -0.15 and a beta of 1.27. The firm has a fifty day moving average price of $4.73 and a 200-day moving average price of $6.03. Biora Therapeutics has a 1 year low of $1.76 and a 1 year high of $19.90.

Biora Therapeutics Company Profile

(Get Free Report)

Biora Therapeutics, Inc, a clinical-stage biotechnology company, engages in developing oral biotherapeutics in the United States. The company offers NaviCap, a targeted oral delivery platform for delivery of therapeutics in the gastrointestinal tract to enhance the treatment of inflammatory bowel diseases; and BioJet, a systemic oral delivery platform designs to replace injection with needle-free, oral delivery of large molecules for management of chronic diseases.

See Also